New insider activity at Biogen ( (BIIB) ) has taken place on March 11, 2025.
Director Stephen Sherwin has recently sold 8,760 shares of Biogen stock, amounting to a total transaction value of $1,314,087.
Recent Updates on BIIB stock
In the last 24 hours, Biogen has faced significant developments impacting its stock. The Therapeutic Goods Administration of Australia declined approval for Biogen and Eisai’s lecanemab for early Alzheimer’s, citing a narrow indication that would limit patient access. This decision contrasts with approvals in eleven other countries, prompting Biogen to consider further actions to ensure access in Australia. Additionally, the European Medicines Agency’s Committee for Medicinal Products for Human Use reaffirmed a positive opinion for lecanemab, which may influence future European Commission decisions. These regulatory updates have contributed to market reactions and analyst considerations regarding Biogen’s stock price and future prospects.
More about Biogen
YTD Price Performance: 0.25%
Average Trading Volume: 1,543,468
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $22.01B
Questions or Comments about the article? Write to editor@tipranks.com